Exelixis reported $13.2M in Cost of Sales for its first fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Cost Of Sales Change
Acadia Pharmaceuticals ACAD:US $ 2.95M 0.39M
Akebia Therapeutics AKBA:US $ 23.02M 19.35M
Amgen AMGN:US $ 1561M 157M
AstraZeneca AZN:LN 2279M 790M
Bayer BAYN:GR € 5176M 1491M
Biomarin Pharmaceutical BMRN:US $ 116.96M 2.78M
Bristol Myers Squibb BMY:US $ 2471M 115M
Eisai 4523:JP Y 50738M 6516M
Eli Lilly And LLY:US $ 2072.1M 21.9M
Esperion Therapeutics ESPR:US $ 7.12M 2.05M
Exelixis EXEL:US $ 13.2M 0.29M
Glaxosmithkline GSK:US $ 3645M 30M
IONIS PHARMACEUT IONS:US $ 4.17M 1.94M
MacroGenics MGNX:US 48K 899K
Merk MRK:US $ 5334M 1507M
Moderna Inc MRNA:US 1.02B 65M
Nektar Therapeutics NKTR:US $ 5.32M 0.85M
Neurocrine Biosciences NBIX:US $ 4.6M 0.5M
Novartis NOVN:VX SF 3755M 245M
Pfizer PFE:US $ 10010M 399M
Puma Biotechnology PBYI:US $ 10.84M 1.05M
Seattle Genetics SGEN:US $ 87.63M 0.94M
Takeda 4502:JP Y 308380M 26976M
Ultragenyx Pharmaceutical RARE:US $ 6.1M 2.59M
YTE INCY:US $ 37.21M 1.36M